Protein binding of sulphachlorpiridacine
Mariño, E.L.; Tabernero, J.M.; Macías, J.G.; Domínguez-Gil, A.; de Castro, S.
Archivos de Farmacologia y Toxicologia 5(2): 107-116
1979
ISSN/ISBN: 0304-8616 PMID: 533316 Document Number: 150111
Sulfachlorpyridazine is bound to plasma proteins in high proportions (94-98%) when therapeutic concentrations are achieved for this antimicrobial agent. The kinetic studies of Scatchard, Klotz and Scott demonstrate that in the serum albumin binding levels of the drug, there are at least 2 different class of binding sites and 2 association constants. The capacity of plasma protein binding of sulfachlorpyridazine is studied in vitro and in vivo by ultrafiltration. The binding to plasma proteins is unaltered in the case of patients with moderate hepatic impairment but is significantly reduced in patients with renal impairment. This reduction is interpreted as being a consequence of the presence in the serum of uremic patients of substances which are removed by ultrafiltration and which compete with the drug for the binding process to protein molecules.